International Agency for Research on Cancer (IARC) - Summaries & Evaluations
For definition of Groups, see Preamble Evaluation.
Supplement 7: (1987) (p. 347)
CAS No.: 127-69-5
Chem. Abstr. Name: Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-
A. Evidence for carcinogenicity to humans (inadequate)
No significant association with cancer at any site was oberved
during 1969-1976 among 11 659 members of a prepaid health plan
prescribed sulfafurazole during 1969-1973 [ref: 1].
B. Evidence for carcinogenicity to animals (inadequate)
Sulfafurazole was tested in mice and rats by oral administration;
no increase in tumour incidence was observed [ref: 2].
C. Other relevant data
No data were available to the Working Group.
Sulfafurazole (sulphisoxazole) is not classifiable as to its carcinogenicity to humans (Group 3).
For definition of the italicized terms, see
Also see previous evaluation:
Vol. 24 (1980)
1. Friedman, G.D. & Ury, H.K. (1980) Initial screening for
carcinogenicity of commonly used drugs. J. natl Cancer Inst., 65,
2. IARC Monographs, 24, 275-285, 1980
- Azo gantrisin
- NU 445
Last updated: 11 March 1998